| Literature DB >> 36001378 |
Jordan M Neil1, Christian Senecal2, Lauren Ballini2, Yuchiao Chang3, Brett Goshe4, Efren Flores5, Jamie S Ostroff6, Elyse R Park4.
Abstract
BACKGROUND: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.Entities:
Keywords: cancer; message framing; recruitment; smoking; teachable moment; tobacco treatment trial
Year: 2022 PMID: 36001378 PMCID: PMC9453579 DOI: 10.2196/37526
Source DB: PubMed Journal: JMIR Cancer ISSN: 2369-1999
Intervention conditions (3-factor, fully crossed factorial design).
| Condition | Threat of continued smoking (distal vs proximal) | Response efficacy to quit smoking (cost vs benefit) | Response efficacy of participating in the study (gain vs loss) |
| 1 | Proximal | Cost | Loss |
| 2 | Proximal | Cost | Gain |
| 3 | Proximal | Benefit | Gain |
| 4 | Proximal | Benefit | Loss |
| 5 | Distal | Cost | Gain |
| 6 | Distal | Cost | Loss |
| 7 | Distal | Benefit | Loss |
| 8 | Distal | Benefit | Gain |
| 9 (control) | N/Aa | N/A | N/A |
aN/A: not applicable.
Figure 1CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
Participant characteristics compared across 9 conditions (N=76).
| Participant | Total | Control | Proximal, cost, loss | Proximal, cost, gain | Proximal, benefit, gain | Proximal, benefit, loss | Distal, cost, gain | Distal, cost, loss | Distal, benefit, loss | Distal, benefit, gain | |||||||||||||
| Age (years), mean (SD) | 53.4 (1.6) | 57.6 (17.8) | 59.7 (11.9) | 48.5 (16.9) | 54.8 (11.3) | 63.8 (9.2) | 52.9 (15.1) | 49.1 (12.6) | 52.9 (12.4) | 45.4 (15.0) | |||||||||||||
|
| |||||||||||||||||||||||
|
| Male | 42 (55) | 5 (71) | 4 (57) | 7 (64) | 1 (11) | 3 (50) | 9 (69) | 4 (57) | 4 (44) | 5 (71) | ||||||||||||
|
| Female | 34 (45) | 2 (29) | 3 (43) | 4 (36) | 8 (89) | 3 (50) | 4 (31) | 3 (43) | 5 (56) | 2 (29) | ||||||||||||
|
| |||||||||||||||||||||||
|
| White | 65 (86) | 6 (86) | 5 (71) | 9 (82) | 7 (77.8) | 6 (100) | 13 (100) | 6 (86) | 8 (89) | 5 (71) | ||||||||||||
|
| Non-White | 11 (15) | 1 (14) | 2 (29) | 2 (18) | 2 (22) | 0 (0) | 0 (0) | 1 (14) | 1 (11) | 2 (29) | ||||||||||||
|
| |||||||||||||||||||||||
|
| Hispanic | 7 (9) | 0 (0) | 1 (14) | 0 (0) | 0 (0) | 1 (17) | 1 (8) | 2 (29) | 0 (0) | 2 (29) | ||||||||||||
|
| |||||||||||||||||||||||
|
| After high school education | 62 (82) | 6 (96) | 4 (57) | 11 (100) | 6 (67) | 4 (67) | 12 (92) | 7 (100) | 7 (78) | 5 (71) | ||||||||||||
|
| |||||||||||||||||||||||
|
| Insured | 73 (96) | 6 (86) | 7 (100) | 11 (100) | 8 (89) | 6 (100) | 13 (100) | 6 (86) | 9 (100) | 7 (100) | ||||||||||||
|
| |||||||||||||||||||||||
|
| ≥40,000 | 56 (74) | 6 (86) | 4 (57) | 9 (82) | 5 (56) | 3 (50) | 8 (62) | 7 (100) | 8 (89) | 6 (86) | ||||||||||||
|
| |||||||||||||||||||||||
|
| <6 | 29 (38) | 2 (29) | 5 (71) | 4 (36) | 3 (33) | 2 (33) | 5 (39) | 2 (29) | 4 (44) | 2 (29) | ||||||||||||
|
| 7-12 | 28 (37) | 3 (43) | 1 (1) | 3 (27) | 3 (33) | 2 (33) | 5 (39) | 4 (57) | 3 (33) | 4 (57) | ||||||||||||
|
| 13-24 | 19 (25) | 2 (29) | 1 (14) | 4 (36) | 3 (33) | 2 (33) | 3 (23) | 1 (14) | 2 (22) | 1 (14) | ||||||||||||
|
| |||||||||||||||||||||||
|
| Prostate | 7 (9) | 0 (0) | 1 (14) | 4 (36) | 1 (11) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (14) | ||||||||||||
|
| Lung | 5 (7) | 0 (0) | 0 (0) | 1 (9) | 0 (0) | 0 (0) | 1 (8) | 2 (29) | 0 (0) | 1 (14) | ||||||||||||
|
| Breast | 10 (13) | 1 (14) | 0 (0) | 2 (18) | 3 (33) | 1 (17) | 0 (0) | 1 (14) | 2 (22) | 0 (0) | ||||||||||||
|
| Pancreatic | 3 () | 0 (0) | 2 (29) | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 0 (0) | 0 (0) | ||||||||||||
|
| Skin | 23 (30) | 1 (14) | 3 (43) | 2 (18) | 1 (11) | 2 (33) | 4 (31) | 2 (29) | 5 (56) | 3 (43) | ||||||||||||
|
| Stomach | 3 (4) | 1 (14) | 0 (0) | 1 (9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 () | 1 (14) | ||||||||||||
|
| Gynecological | 7 (9) | 0 (0) | 0 (0) | 1 (9) | 2 (22) | 1 (17) | 1 (8) | 1 (14) | 1 (11) | 0 (0) | ||||||||||||
|
| Colorectal | 7 (9) | 1 (14) | 1 (14) | 0 (0) | 0 (0) | 0 (0) | 2 (15) | 1 (14) | 1 (11) | 1 (14) | ||||||||||||
|
| Other | 10 (13) | 2 (29) | 0 (0) | 0 (0) | 2 (22) | 2 (33) | 4 (31) | 0 (0) | 0 (0) | 0 (0) | ||||||||||||
|
| Never screened for any test | 1 (1) | 1 (14) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||||||||
|
| |||||||||||||||||||||||
|
|
| ||||||||||||||||||||||
|
|
| Values, mean (SD) | 3.90 (0.65) | 3.73 (0.76) | 3.93 (0.68) | 3.73 (0.78) | 3.75 (0.49) | 4.31 (0.39) | 3.78 (0.71) | 3.88 (0.77) | 4.14 (0.34) | 4.09 (0.77) | |||||||||||
|
|
| Values, range | 2.0-5.0 | 2.4-4.5 | 2.5-4.5 | 2.3-4.9 | 2.9-4.4 | 3.8-4.8 | 2.0-4.5 | 2.8-5.0 | 3.8-4.8 | 2.6-5.0 | |||||||||||
|
|
| ||||||||||||||||||||||
|
|
| Values, mean (SD) | 28.93 (16.41) | 33.29 (22.49) | 27.86 (15.77) | 24.00 (19.69) | 33.67 (8.65) | 38.00 (15.79) | 32.46 (16.25) | 23.71 (14.87) | 25.67 (14.14) | 22.43 (18.28) | |||||||||||
|
|
| Values, range | 2-57 | 2-54 | 10-50 | 2-54 | 17-42 | 18-55 | 10-55 | 5-45 | 3-51 | 2-57 | |||||||||||
|
|
| ||||||||||||||||||||||
|
|
| Values, mean (SD) | 11.84 (7.91) | 13.57 (10.53) | 6.86 (3.67) | 12.09 (4.89) | 9.67 (5.92) | 15.67 (7.53) | 12.92 (7.92) | 9.00 (8.64) | 13.25 (11.30) | 13.43 (10.05) | |||||||||||
|
|
| Values, range | 0-35 | 0-30 | 3-12 | 5-20 | 0-18 | 9-30 | 0-30 | 0-25 | 0-35 | 2-30 | |||||||||||
|
| |||||||||||||||||||||||
|
| >30 | 24 (32) | 2 (29) | 2 (29) | 4 (363) | 5 (56) | 0 (0) | 3 (23) | 3 (43) | 4 (44) | 1 (14) | ||||||||||||
|
| <30 | 51 (67) | 5 (71) | 5 (71) | 7 (64) | 4 (44) | 6 (100) | 10 (77) | 4 (57) | 4 (44) | 6 (86) | ||||||||||||
|
| |||||||||||||||||||||||
|
| Values, mean (SD) | 8.28 (1.86) | 7.71 (2.36) | 9.43 (0.79) | 8.60 (1.58) | 8.00 (2.18) | 7.00 (2.97) | 8.31 (1.49) | 8.00 (2.38) | 8.44 (1.51) | 8.71 (1.38) | ||||||||||||
|
| Values, range | 3-10 | 5-10 | 8-10 | 6-10 | 4-10 | 3-10 | 6-10 | 3-10 | 5-10 | 7-10 | ||||||||||||
|
| |||||||||||||||||||||||
|
| Values, mean (SD) | 7.07 (2.41) | 7.00 (1.83) | 8.43 (1.51) | 6.73 (2.57) | 7.33 (2.06) | 6.83 (2.48) | 5.38 (3.07) | 8.00 (0.82) | 7.33 (3.00) | 8.00 (1.73) | ||||||||||||
|
| Values, range | 1-10 | 5-10 | 6-10 | 2-10 | 3-10 | 3-10 | 1-10 | 7-9 | 2-10 | 5-10 | ||||||||||||
|
| |||||||||||||||||||||||
|
| Values, mean (SD) | 4.96 (2.73) | 4.86 (3.19) | 5.57 (2.23) | 3.45 (2.21) | 6.22 (2.95) | 5.17 (1.94) | 5.08 (3.15) | 4.29 (2.75) | 5.67 (3.43) | 4.57 (1.90) | ||||||||||||
|
| Values, range | 1-10 | 1-10 | 1-8 | 1-6 | 1-10 | 3-8 | 1-10 | 2-10 | 1-10 | 1-7 | ||||||||||||
|
| |||||||||||||||||||||||
|
| Values, mean (SD) | 2.94 (1.08) | 3.17 (0.75) | 2.67 (1.63) | 2.64 (1.21) | 2.75 (1.16) | 2.83 (0.75) | 2.85 (0.90) | 3.17 (1.17) | 3.14 (1.21) | 3.57 (0.98) | ||||||||||||
|
| Values, range | 1-5 | 2-4 | 1-5 | 1-5 | 2-5 | 2-4 | 2-5 | 1-4 | 1-5 | 2-5 | ||||||||||||
Main effects for message evaluation, message effectiveness, and message intent for each message factor.
| Message factor | Control, mean (SD) | Distal, mean (SD) | Proximal, mean (SD) | Cost, mean (SD) | Benefit, mean (SD) | Gain, mean (SD) | Loss, mean (SD) | ||||
|
| |||||||||||
|
| Message relevance | 3.50 (1.29) | 3.99 (0.87) | 4.18 (0.84) | .34 | 4.16 (0.81) | 3.98 (0.90) | .40 | 4.06 (0.82) | 4.10 (0.91) | .85 |
|
| Message credibility | 3.95 (0.78) | 4.46 (0.68) | 4.29 (0.63) | .29 | 4.38 (0.62) | 4.39 (0.71) | .95 | 4.33 (0.68) | 4.45 (0.64) | .48 |
|
| Message clarity | 4.43 (0.68) | 4.64 (0.64) | 4.64 (0.64) | .99 | 4.58 (0.68) | 4.71 (0.53) | .39 | 4.58 (0.64) | 4.72 (0.59) | .33 |
|
| |||||||||||
|
| Improved perceptions about smoking cessation research | 3.43 (0.79) | 4.14 (0.87) | 4.15 (0.80) | .95 | 4.18 (0.80) | 4.10 (0.87) | .67 | 3.98 (0.83)b | 4.38 (0.78)b | .04b |
|
| Informed decision-making about participating in a smoking cessation research study | 4.71 (0.49) | 4.22 (0.83) | 4.36 (0.74) | .46 | 4.29 (0.80) | 4.29 (0.78) | 1.0 | 4.30 (0.72) | 4.28 (0.88) | .90 |
|
| Interest in further information about participating in a smoking cessation research study | 4.14 (1.57) | 4.83 | 5.55 | .04b | 5.18 | 5.16 | .95 | 5.15 | 5.21 | .87 |
|
| |||||||||||
|
| Intent to talk to a physician about participating in a smoking cessation research study | 4.43 (2.07) | 4.78 | 4.67 | .80 | 5.13 | 4.23 | .04b | 4.60 | 4.90 | .51 |
aP values are for comparison of main effects between message factor levels.
bP values <.05
Multivariable predictors of intent to speak to a physician about enrolling in a smoking cessation research study.
| Predictor | β | SE | 95% CI | ||
| Age (years) | −.01 | 0.01 | −0.88 | .38 | −0.03 to 0.01 |
| Gender (male) | −.90 | 0.32 | −2.85 | .006 | −1.54 to −0.27 |
| Urge to smoke | .30 | 0.15 | 1.94 | .06 | −0.01 to 0.61 |
| Quit importance | .17 | 0.09 | 1.82 | .07 | −0.02 to 0.36 |
| Quit confidence | .09 | 0.08 | 1.11 | .27 | −0.07 to 0.24 |
| Improved perceptions about smoking cessation research | −.09 | 0.22 | −0.40 | .69 | −0.52, 0.35 |
| Message relevance | .77 | 0.22 | 3.58 | .001 | 0.34 to 1.20 |
| Cost versus benefit condition (cost as referent) | −.29 | 0.32 | −0.91 | .37 | −0.93 to 0.35 |
Selection of an exemplary quote for each theme, along with the frequency of hits for each theme and condition for each quote (N=111 hits).
| Theme | Theme definition | Hits of a theme among responses, n (%) | Quote | Participant condition |
| Smoking behavior and perceptions | Participants’ perceptions about their smoking habits | 38 (34.2) | “[The speaker] got me to thinking about my smoking habits, even though I only smoke 4 cigarettes per day.” | Proximal, cost, loss |
| Motivation or readiness to quit | Participants’ interest, motivation, and readiness to quit smoking | 18 (16.2) | “It gave me different options to quit smoking. I really do want to quit, but I don’t think I can.” | Control |
| How informative the video was | Participants’ explanations of the video being informative | 17 (15.3) | “It was very informative and interesting. Being honest about smoking will help in heath related issues” | Distal, benefit, gain |
| Cancer diagnosis | Participants’ framing of the aspects of the video with regard to their cancer diagnosis | 9 (8.1) | “The speaker brought up some good points, such as lower energy levels after being diagnosed with cancer. My energy level hasn’t regained to where I want it to be since prostate surgery.” | Proximal, cost, loss |
| How relevant the video was | Participants’ descriptions of the video as beneficial or not for people like them | 8 (7.2) | “I felt that by joining the study I could get the help I need to stop smoking” | Distal, benefit, gain |
| Evaluation of the tobacco treatment services offered in the study | Participants’ overall perception of the uniqueness of the program, both positive and negative | 7 (6.3) | “A generous offer to participate but nothing presented was unique in that all outlined methods of smoking cessation therapy are already readily available.” | Distal, benefit, loss |
| Overall opinion of the video | Participants’ overall opinion of the video | 6 (5.4) | “It was a very informative and interesting video. I enjoyed watching it.” | Proximal, benefit, loss |
| Evaluation of the speaker in the video | Participants’ reactions and feedback regarding the video speaker | 2 (1.8) | “The speaker was very professional, and not scolding or condescending.” | Distal, cost, loss |
Figure 2Leximancer-generated concept map detailing participant responses when asked to evaluate the video.